IDEXX Laboratories (NASDAQ:IDXX) Price Target Raised to $510.00

IDEXX Laboratories (NASDAQ:IDXX) had its price target hoisted by Piper Sandler from $435.00 to $510.00 in a report released on Monday,Benzinga reports. Piper Sandler currently has a neutral rating on the stock.

A number of other analysts have also recently issued reports on the company. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective on the stock. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, Bank of America raised their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Trading Down 1.4 %

Shares of IDXX stock opened at $457.35 on Monday. IDEXX Laboratories has a 1 year low of $398.50 and a 1 year high of $583.39. The company’s fifty day simple moving average is $429.67 and its two-hundred day simple moving average is $453.23. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 1.03. The stock has a market capitalization of $37.45 billion, a price-to-earnings ratio of 42.86, a PEG ratio of 3.47 and a beta of 1.37.

Insider Transactions at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,330 shares of company stock valued at $6,161,276. Insiders own 2.11% of the company’s stock.

Institutional Trading of IDEXX Laboratories

Several hedge funds and other institutional investors have recently bought and sold shares of IDXX. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories during the third quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares during the last quarter. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth $30,000. Finally, Ashton Thomas Securities LLC purchased a new stake in IDEXX Laboratories during the third quarter valued at about $37,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.